China: Life Sciences, Biotechnology & Nanotechnology

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

Judicial Assessment Of Usage Limitations' Impact On The Novelty Of Product Claims

The SPC pointed out in an administrative appeal that, for product claims containing a subject name with usage limitation, the usage limitation must be considered when determining the scope of protection.

AC

AFD China

外資の研究開発投資が拡大　中国、世界のイノベーション拠点

外資系企業による中国での研究開発投資が拡大している。今年1〜2月に新設された外資系企業は8631社に上り、前年同期比で14％増加した...

China Government

K

Kangxin

A Stratification Too Far? How The CNIPA Draws The Line On Patient Subgroups In A Recent Precision Medicine Invalidation Case

Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions.

EI

Eagle IP

China’s Pharma Innovators Pursue A Range Of Deal Structures To Support Global Expansion

China has emerged as a global pharmaceutical innovation powerhouse, leveraging its scientific expertise, AI capabilities, and streamlined regulatory environment to accelerate drug development.

China Healthcare

AO

A&O Shearman

ライブ販売の商標侵害に厳罰山東高裁、懲罰的賠償で抑止強化

K

Kangxin

世界初の「動画MRI」実用化　中国企業、AI技術でリアルタイム撮影

K

Kangxin

USITC Will Investigate State Support And Pricing Practices By Chinese Biotechnology Firms

China Healthcare

BC

Bergeson & Campbell

China Life Sciences: 2025 Year In Review

China Healthcare

AP

Arnold & Porter

开启直播电商合规新纪元 |《直播电商监督管理办法》重点解读（下）

China Media & IT

FP

Fangda Partners

A Legal Commentary On The Latest Implementing Regulations Of The PRC Drug Administration Law

China Healthcare

FP

Fangda Partners

China Newsletter | Q3 2025/Issue No. 65

GT

Greenberg Traurig, LLP

Navigating China's Health Transformation: Opportunities And Challenges For Multinationals

China Healthcare

AC

Ankura Consulting Group LLC

Tips For Pharmaceutical Use Claims

CT

Chang Tsi & Partners

Ten Minefields: A Guide To Avoiding Pitfalls In Applying For Human Genetic Resources Projects In China

China Healthcare

HK

Han Kun Law Offices

新《公司法》视野下股东出资加速到期与追加被执行人的法律实务分析

China Commercial

AB

AnJie Broad Law Firm

规行矩步，进而有为——中国私募基金行业年度观察报告（2025）

China Commercial

FP

Fangda Partners

信用证下倒签与顺签及重复签发纸质提单和电放提单（surendered Bills Of Lading）的法律后果：浙江省高级人民法院二审"宁波南衡进出口有限公司与株式会社新韩银行信用证纠纷案"判决书简述与点评

China Commercial

JT

Beijing Jincheng Tongda & Neal Law Firm

Inside Arbitration Issue 21: Perspectives On Cross-border Disputes

Worldwide Litigation

KL

Herbert Smith Freehills Kramer LLP

PRC Financial Regulation Annual Report (2026) General

FP

Fangda Partners

China Released Draft Medical Device Law For Comments

On August 28, 2024, the National Medical Products Administration (NMPA) released the Medical Device Administration Law (Draft for Comment)...

China Healthcare

HK

Han Kun Law Offices

Understanding China's Pharmaceutical Patent Linkage System: Framework And Case Overview (Part 1)

The fourth amendment to the Patent Law of the People's Republic of China (hereinafter, the "Patent Law") came into effect on June 1, 2021. In July of the same year, the Measures for the Implementation...

CT

Chang Tsi & Partners

生物医药领域符合WIPO标准ST.26的序列表制作经验

在生物医药领域，对于涉及氨基酸序列和/或核苷酸序列的发明专利申请，通常需要制作符合特定标准的序列表...

CP

CCPIT Patent & Trademark Law Office

China Life Sciences Compliance Update: Insurance Fraud Enforcement Campaign And New Ethical Code For HCPs

Chinese authorities have launched a special "Hundred-Day Campaign" to target misconduct relating to China's state-run medical insurance program and issued a new Ethical Code for Healthcare Professionals...

China Healthcare

AP

Arnold & Porter

China Life Sciences Compliance Update: Kickback And Third-Party Case Study

China Healthcare

AP

Arnold & Porter

Understanding The EU's International Procurement Instrument

China Government

CM

Crowell & Moring LLP

汉坤 • 观点 | 《药品管理法实施条例》（修订草案）重点快评

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 中国药品年度报告制度简析

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 简评新版《医疗器械临床试验质量管理规范（GCP）》

China Healthcare

HK

Han Kun Law Offices

Compliance Highlights And Strategies In High-Risk Clinical Research Landscape

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Settle The Dust Or Let The Bullets Fly: Biden Administration Signs Executive Order On Promoting Biotechnology And Biomanufacturing Innovation

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Settle The Dust Or Let The Bullets Fly: Biden Administration Signs Executive Order On Promoting Biotechnology And Biomanufacturing Innovation

On September 12, 2022, U.S. President Joe Biden signed the Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Finally Waiting For You - Interpreting The New Policy Of Cross-border Contract Production Of Drugs And Medical Devices In The Guangdong-Hong Kong-Macao Greater Bay Area

On June 29, 2022, the National Medical Products Administration ("NMPA") publicly released the "Implementation Plan for Supporting Hong Kong and Macao Drug Marketing Authorization Holders...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Of Our Country's Drug Review And Approval System (Part II)

In "Interpretation of China's Annual Drug Review Report (2015-2021) - Review of the Achievements of China's Drug Review and Approval System Reform (Part 1)"...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of China's Annual Drug Review Report (2015-2021) - Review Of The Reform Achievements Of Our Country's Drug Review And Approval System (Part II)

In the "Interpretation of China's Annual Drug Evaluation Report (2015-2021) - Review of the Achievements of China's Drug Evaluation and Approval System Reform (Part 1)", we have summarized and refined the key contents...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 医药BD项目如何友好"分手"？

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Key Points For The Supervision Of Medical And Three-Product And One-Device Advertising Under The New Regulations On Internet Advertising

On March 24, 2023, the State Administration for Market Regulation publicly issued the "Measures for the Administration of Internet Advertising" (the "Measures")...

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Brief Review Of The Measures For The Review Of Science And Technology Ethics (Trial) (Draft For Comments)

On April 4, 2023, the Ministry of Science and Technology released the "Measures for Science and Technology Ethics Review (Trial) (Draft for Comments)" ("Draft for Comments")...

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | CAR-T/NK监管路在何方 — 体细胞临床研究工作指引（征求意见稿）要点解读

2023年5月9日，国家卫健委科教司发布《体细胞临床研究工作指引（征求意见稿）》（" 《征求意见稿》"），并面向社会公开征求意见。体细胞治疗

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Interpretation Of The New Administrative Guidelines For Human Genetic Resources

On July 14, 2023, the Ministry of Science and Technology (hereinafter referred to as the "Ministry of Science and Technology") issued the "Notice on Updating the Service Guidelines...

China Healthcare

HK

Han Kun Law Offices

Strategic Insights For The Localization Of Pharmaceutical And Medical Device Manufacturing In China

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | LDT试点新规解读

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Blockbuster Debut: Interpretation Of The Key Points Of The Implementation Rules Of The Regulations On The Management Of Human Genetic Resources

China Healthcare

HK

Han Kun Law Offices

观点 | 生命科学行业License-in/out合同争议要点分析（四）：首付款是否可能退回？

China Commercial

HK

Han Kun Law Offices

药企出海新热点：管线分拆"SON"模式的实践解读

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | Breaking News: 10 Questions And Answers On Pharmaceutical Anti-Corruption In 2023

China Healthcare

HK

Han Kun Law Offices

Han Kun Opinion | CAR-T/NK Regulatory Decisions — Interpreting The "Guidelines For Somatic Cell Clinical Research (Trial)"

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 从药械产品全生命周期视角解读License-in/out许可交易项目合作条款要点

China Healthcare

HK

Han Kun Law Offices

汉坤 • 观点 | 企业或需自设伦理委员会：《科技伦理审查办法（试行）》正式出台

China Healthcare

HK

Han Kun Law Offices

Han Kun • Viewpoint | Interpretation Of The "Annual Report On The Progress Of Clinical Trials For New Drug Registration In China (2022)"

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | 2023 Life Sciences Regulatory Compliance Annual Summary

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Quick Review Of The New Regulations: Interpret The Latest Questions And Answers Of The Ministry Of Science And Technology

China Healthcare

HK

Han Kun Law Offices

Han Kun • Quick Comment | Is The Transmission Of Cross-border Genomic Data Between China And The United States Blocked? Biden Data Executive Order Quick Review

China Healthcare

HK

Han Kun Law Offices

Han Kun • Opinion | Analysis Of Key Points Of License-In/out Contract Disputes In The Life Sciences Industry (1): Joint Steering Committee, Reasonable Commercial Efforts, Confidentiality Obligations

China Healthcare

HK

Han Kun Law Offices

Hankun • Quick Comment | The Regulations On Human Genetic Resources Management Are Revised Again

China Healthcare

HK

Han Kun Law Offices

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More